EMA Backs New Method For Measuring Alzheimer’s Disease In Trials

Evidence generated through an EU public-private funding initiative has resulted in a new biomarker method for measuring the level of Alzheimer’s disease in a person’s brain, which drug developers can use during clinical trials.